We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
EQL.ST

Price
52.10
Stock movement up
+1.60 (2.71%)
Company name
EQL Pharma AB
Exchange
(ST
,
Currency
SEK
)
Market cap
-
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
4.75%
Div growth
8.43%
Growth years
1
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-10-31

DIVIDENDS

Dividend yield - 5y

Dividend yield data
Dividend per share2.88
Dividend yield4.75%
Payout frequencyQuarterly
Maximum yield5.03%
Average yield4.53%
Minimum yield-
Discount to avg yield4.68%
Upside potential4.91%
Yield as % of max yield94.40%

Yield distribution (inverse percentile) - 5y

Yield distribution data
Dividend yield4.75%
Current yield distribution53.57%
Yield at 100% (Min)-
Yield at 90%4.30%
Yield at 80%4.38%
Yield at 50% (Median)4.76%
Yield at 20%4.88%
Yield at 10%4.92%
Yield at 0% (Max)5.03%

Dividend per share

Dividend per share data
Years of growth1 years
CCC status-
Dividend per share2.88
Payout frequencyQuarterly
Ex-div date22 Dec 2022
EPS (TTM)-
EPS (1y forward)2.28
EPS growth (5y)-
EPS growth (5y forward)-

Dividend growth

Please create a free account or log in to access this chart
Dividend growth data
EQL.STS&P500
DGR MR33.61%-13.74%
DGR TTM10.93%6.60%
DGR 3 years9.55%7.31%
DGR 5 years8.43%4.69%
DGR 10 years9.44%6.30%
DGR 15 years-8.16%
Time since last change announced1070 days
EPS growth (5y)-
EPS growth (5y forward)-

Payout ratio

Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM--
Average--
Forward--

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

FINANCIALS

Per share

Per share data
Current share count-
EPS (TTM)-
FCF per share (TTM)-

Income statement

Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)2.28

Margins

Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash56.11M
Net receivables123.35M
Total current assets370.81M
Goodwill0.00
Intangible assets420.50M
Property, plant and equipment0.00
Total assets797.28M
Accounts payable64.77M
Short/Current long term debt0.00
Total current liabilities195.96M
Total liabilities566.41M
Shareholder's equity230.87M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Stock price data
Open59.00
Daily high60.70
Daily low58.30
Daily Volume9K
All-time high69.90
1y analyst estimate80.00
Beta0.54
EPS (TTM)-
Dividend per share2.88
Ex-div date22 Dec 2022
Next earnings date-

Downside potential

Downside potential data
EQL.STS&P500
Current price drop from All-time high-25.46%-4.13%
Highest price drop-18.03%-19.00%
Date of highest drop22 Oct 20258 Apr 2025
Avg drop from high-11.20%-2.73%
Avg time to new high9 days6 days
Max time to new high26 days89 days
COMPANY DETAILS
EQL.ST (EQL Pharma AB) company logo
Marketcap
-
Marketcap category
Small-cap
Description
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
Employees
21
Website
https://www.eqlpharma.com
Investor relations
-
SEC filings
EQL.ST SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
EQL Pharma (OM:EQL) Margin Miss Challenges Bullish Growth Narrative Despite Strong Forecasts
EQL Pharma (OM:EQL) is forecasting robust growth, with earnings expected to climb 59.6% per year and revenue set to increase 30.4% per year, both well ahead of broader Swedish market expectations. How...
November 6, 2025
EQL Pharma AB (OSTO:EQL) Q2 2026 Earnings Call Highlights: Navigating Supply Chain Challenges ...
Despite a challenging quarter with supply chain disruptions, EQL Pharma AB (OSTO:EQL) focuses on strategic launches and market expansions to drive future growth.
November 5, 2025
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesFeatured ArticlesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved